Subject: Change of Indirect Cost Rate for Industry Funded PI-Initiated Clinical Trials

Effective July 1, 2016, the indirect cost (IDC) rate for any new Industry funded PI-initiated clinical trial agreement being considered for negotiation and execution will be increased to 30% (from 26%), aligning the rate for all clinical trials (PI-initiated and Sponsored-initiated). Earlier this year the indirect cost (IDC) rate for sponsor-initiated clinical trials was increased from 26% percent to 30% effective July 1, 2016.

This is the first increase to the clinical trial IDC rate since 2006, and is equal or below the rate charged at other major research universities including Baylor, Columbia, Case Western Reserve, Harvard, UCSF and USC.

The 26% rate will be permitted to continue for the remaining term of existing agreements so that investigators with clinical trials underway are not disadvantaged. All new proposals and renewals (where discussions and negotiations commence for a proposed new Industry funded, PI-initiated clinical trial) will be budgeted at the higher rate.

For Industry funded PI-initiated clinical trials, the IDC rate is applied on a total direct cost (TDC) basis, not modified total direct cost (MTDC). Federally funded or non-profit clinical trials use the rate and application methodology associated with the sponsor (up to 55%).

This incremental increase will support the infrastructure required to meet escalating compliance requirements and the needs of the growing clinical research activity. Clinical research remains a critical component of the campus strategic plan.

For more information about the IDC rates for PI-initiated clinical trials, see http://blink.ucsd.edu/research/preparing-proposals/sponsors/clinicaltrials.html#Indirect-Cost-Rate-for-PI-Initi
For guidance regarding the difference between a PI-initiated and Sponsor-initiated clinical trial, see http://blink.ucsd.edu/research/preparing-proposals/clinical-research-trials/pi-vs-industry.html

Sandra A. Brown
Vice Chancellor for Research

Pierre Ouillet
Vice Chancellor and Chief Financial Officer for UC San Diego
Acting Chief Financial Officer for Health Sciences

*------------------------------